Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure1
Why the study?
Does recombinant human growth hormone reduce abdominal fat mass and improve metabolic parameters in abdominally obese men?
Population
30 men, 48-66 years old, with abdominal/visceral obesity
Comparison
Recombinant human growth hormone 9.5… vs Placebo
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
9 months
Authors
Discussion
Loading...
Member takes
Implication
Supports rhGH consideration for visceral obesity in men; confirms metabolic benefits in this RCT.
Structured PICO
Does recombinant human growth hormone reduce abdominal fat mass and improve metabolic parameters in abdominally obese men?
P
Population
30 men, 48-66 years old, with abdominal/visceral obesity
I
Intervention
Recombinant human growth hormone (rhGH) 9.5 micrograms/kg daily for 9 months
C
Comparator
Placebo
O
Outcome
Changes in total body fat, abdominal subcutaneous and visceral adipose tissue, glucose disposal rate, lipid profile, and blood pressure at 9 monthssurrogate
Growth hormone treatment in abdominally obese men reduces visceral fat and improves insulin sensitivity, lipid profile, and diastolic blood pressure.
Cite This Study
Johannsson et al. (1997) studied this question.